The discovery of neuropeptides as signaling molecules with paracrine or hormonal regulatory functions has led to trailblazing advances in physiology and fostered the characterization of numerous neuropeptide-binding G-protein coupled receptors (GPCRs) as potential drug targets. The impact on human health has been tremendous: approximately 30% of commercial drugs act via the GPCR pathway. However, about 25% of the GPCRs encoded by the mammalian genome still lack their pharmacological identity. Searching for the orphan GPCR endogenous ligands that likely are neuropeptides has proved to be a formidable task. Here we describe the mass spectrometry-based technologies and experimental strategies that have been successful in achieving high throughput characterization of endogenous peptides in nervous and endocrine systems.
Keywordsbioinformatics; endogenous peptides; sequencing; mass spectrometry; nervous system; quantitation
What is peptidomics?Genome and transcriptome sequencing is upon us, so why we are still looking for ways to identify bioactive peptides in living systems? Bold genomic research efforts have provided extraordinary insights into the inventory of GPCR-receptor genes, the most coveted targets in drug development [1]. Gene association and knockout studies have illuminated the roles of various peptide genes in pathological conditions and diseases in animal models [2,3]. Yet genetic investigations do not determine the actual peptide gene products, neuropeptides, and hormones that mediate vital body functions and complex behaviors. The immense challenge is due to the complexity of molecular readout; a single gene can produce many products as a result of single nucleotide polymorphisms, alternative gene splicing, post-translational processing of precursor proteins, and the addition of chemical post-translational Corresponding author: Sweedler, J.V., jsweedle@illinois.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author ManuscriptAuthor Manuscript
Author ManuscriptAuthor Manuscript modifications (PTMs) of cleaved peptides that oftentimes cannot be inferred from genomic data. Even annotating peptide coding genes and in silico neuropeptidome prediction requires specialized expertise and bioinformatics tools [4][5][6].At the dawn of the new millennium, the term 'peptidomics' (see the workflow shown in Figure 1A) was formally adopted to describe a method for high throughput, direct measurement and structural characterization of the endogenous peptides present in a given biological sample (see detailed historical review by Schrader and co...